Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLEPYN)

Drug Name

Tetramethylammonium Ion Drug Info

Synonyms

Tetramethylammonium; TETRAMETHYLAMMONIUM ION; tetramethylazanium; 51-92-3; N,N,N-trimethylmethanaminium; UNII-H0W55235FC; Tetramethylammonium octahydrotriborate; EINECS 235-626-5; CHEMBL46486; Methanaminium, N,N,N-trimethyl-, octahydrotriborate(1-); CHEBI:46020; Methanaminium, N,N,N-trimethyl-; H0W55235FC; Tetramethylammonium pentaiodide; Tetramethyl-Ammonium; Ammonium, (pentaiodide); AC1L1MEF; 19269-48-8; bmse000780; 64-20-0 (bromide); 75-59-2 (hydroxide); 75-57-0 (chloride); 75-58-1 (iodide); 12386-10-6; 373-68-2 (fluoride)

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 6380
ChEBI ID: CHEMBL46486
CAS Number: CAS 51-92-3
TTD Drug ID: DMLEPYN
VARIDT Drug ID: DR01474

Molecule-Related Drug Atlas

Molecule Type:

DTT

DTP

Drug Status:

Investigative Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting UDP-glucose 4-epimerase (GALE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[1]
PSAMMAPLIN A	DM6T0IQ	Discovery agent	N.A.	Investigative	[3]
UDP-glucose	DMLT4JA	Discovery agent	N.A.	Investigative	[1]
Uridine Diphosphate Galactose	DMPA0BJ	Discovery agent	N.A.	Investigative	[4]
Uridine-Diphosphate-N-Acetylgalactosamine	DMXHO6J	N. A.	N. A.	Investigative	[1]
Uridine-Diphosphate-N-Acetylglucosamine	DMEQSTP	Discovery agent	N.A.	Investigative	[5]
Uridine-5'-Diphosphate	DMDQKJB	Discovery agent	N.A.	Investigative	[1]
Phenyl-Uridine-5'-Diphosphate	DM7J0YG	Discovery agent	N.A.	Investigative	[1]
Uridine-5'-Diphosphate-Mannose	DMAYCQU	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Drug(s) Transported By Organic cation transporter 1 (SLC22A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[6]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[7]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[8]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[9]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[10]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[11]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[12]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[13]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[14]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[15]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
UDP-glucose 4-epimerase (GALE)	TTGRHIB	GALE_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[2]

------------------------------------------------------------------------------------

References

1	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2	Scintillation proximity assay for measuring uptake by the human drug transporters hOCT1, hOAT3, and hOATP1B1. Anal Biochem. 2007 Jul 15;366(2):117-25.
3	Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5744-7.
4	Crystal structure of beta1,4-galactosyltransferase complex with UDP-Gal reveals an oligosaccharide acceptor binding site. J Mol Biol. 2002 Apr 26;318(2):491-502.
5	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
6	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
7	Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
8	Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
9	Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
10	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
11	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
12	Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
13	Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
14	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
15	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.